- Conditions
- Post-traumatic Stress Disorder (PTSD), Post-traumatic Stress Symptoms, Opioid Use Disorder (OUD), Stimulant Use Disorder, Stimulant Use & Co-occuring Opioid Use Disorders, Co-occurring Mental and Substance Use Disorders, Medications for Opioid Use Disorder
- Interventions
- Cognitive Processing Therapy (CPT), Written Exposure Therapy (WET)
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder
- Interventions
- Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
- Behavioral
- Lead sponsor
- Elana Rosenthal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more
- Conditions
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
- Interventions
- Solriamfetol 150 MG, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Bellflower, California • Chino, California + 33 more
- Conditions
- Binge-Eating Disorder
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Encino, California • Garden Grove, California • Long Beach, California + 38 more
- Conditions
- ADHD
- Interventions
- Magnetic Resonance Imaging (MRI), PHNO, calcitriol, Placebo oral capsule, high-resolution research tomography, Dextro Amphetamine
- Procedure · Drug · Dietary Supplement
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Stimulant Use Disorder, People Living With HIV
- Interventions
- reSET, Standard of care
- Behavioral · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sleep Disorder, Healthy
- Interventions
- Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
- Behavioral · Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 48 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- B-MPH
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Naltrexone, Methylphenidate Abuse
- Interventions
- Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
- Drug
- Lead sponsor
- Avekshan LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Substance Use Disorders, Treatment Adherence and Compliance
- Interventions
- KATR Linkage Strategy
- Behavioral
- Lead sponsor
- Terry Bunn
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Berea, Kentucky • Lexington, Kentucky
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- SMS Intervention
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neurofibromatosis Type 1
- Interventions
- CogmedRM, Mobymax
- Other
- Lead sponsor
- Kristina Hardy
- Other
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- ADHD, Autism Spectrum Disorder
- Interventions
- Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
- Drug
- Lead sponsor
- Daniel Coury
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Irvine, California • Los Angeles, California • Portland, Maine + 7 more
- Conditions
- Traumatic Brain Injury
- Interventions
- methylphenidate, Placebo
- Drug
- Lead sponsor
- Uniformed Services University of the Health Sciences
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Narcolepsy
- Interventions
- JZP-258
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 28
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Text- Messaging, Treatment as usual
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
- Interventions
- Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
- Drug · Other
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 1,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 2
- States / cities
- Morrisville, North Carolina • Wilmington, North Carolina
- Conditions
- Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
- Interventions
- Omega-3 Fatty Acid, ADHD Medication
- Dietary Supplement · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ADHD
- Interventions
- CNS Stimulant
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- ADHD
- Interventions
- methylphenidate HCl, Mixed amphetamine salts extended release
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- ADHD
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Encino, California • Garden Grove, California • Newport Beach, California + 37 more
- Conditions
- Methamphetamine Abuse
- Interventions
- Affect Treatment Program for Methamphetamine Use Disorder
- Other
- Lead sponsor
- Affect Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Major Depressive Disorder
- Interventions
- Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Bellflower, California • Encino, California + 35 more